WRBY Warby Parker Inc.
Ophthalmic Goods · NYSE · SEC CIK 1504776 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.9%
TTM net income YoY942.0%
TTM EPS YoY216,172,782,113,783,936.0%
Revenue 3-yr CAGR12.6%
Net income 3-yr CAGR—
Margins
Gross margin54.7%
Operating margin0.2%
Net margin0.8%
FCF margin2.3%
EBITDA margin6.1%
Returns
ROE1.9%
ROA1.0%
ROIC (approx.)1.1%
Asset turnover1.25x
Leverage & solvency
Liabilities / assets49.1%
Debt / equity0.00x
Current ratio2.26x
Interest coverage—
Cash quality & payout
Operating cash flow / net income13.67x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue8.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $871.90M | $771.32M |
| Cost of revenue | $401.33M | $344.48M |
| Gross profit | $470.58M | $426.83M |
| SG&A expense | $475.92M | $456.95M |
| Operating income | -$5.34M | -$30.11M |
| Pretax income | $3.04M | -$19.52M |
| Income tax | $1.40M | $875,000 |
| Net income | $1.64M | -$20.39M |
| EBITDA | $44.94M | $15.75M |
| EPS (basic) | 0.01 | -0.17 |
| EPS (diluted) | 0.01 | -0.17 |
| Weighted avg. shares (diluted) | 125.10M | 120.39M |
| Balance sheet | ||
| Cash & equivalents | $286.36M | $254.16M |
| Receivables | $3.29M | $1.95M |
| Inventory | $44.51M | $52.34M |
| Current assets | $352.44M | $326.05M |
| PP&E, net | $187.45M | $170.46M |
| Total assets | $720.92M | $676.49M |
| Current liabilities | $150.13M | $130.35M |
| Total liabilities | $353.19M | $336.42M |
| Shareholders' equity | $367.73M | $340.07M |
| Cash flow statement | ||
| Operating cash flow | $110.78M | $98.74M |
| Capital expenditure | $67.05M | $64.03M |
| Free cash flow | $43.74M | $34.71M |
| Investing cash flow | -$67.05M | -$66.03M |
| Financing cash flow | -$12.00M | $4.96M |
| Depreciation & amortization | $50.28M | $45.87M |
| Stock-based compensation | $34.54M | $47.29M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.